Global Oligonucleotide Therapeutics Drug 麻豆原创 Research Report 2023

Publication ID:

PB510235972

Publication Date:

October 17, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
The global Oligonucleotide Therapeutics Drug market is projected to reach US$ 499.3 million in 2029, increasing from US$ 325 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oligonucleotide Therapeutics Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oligonucleotide Therapeutics Drug market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oligonucleotide Therapeutics Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Oligonucleotide Therapeutics Drug 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Oligonucleotide Therapeutics Drug 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Neuromuscular Diseases
1.3.3 ATTR
1.3.4 Hepatic VOD
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapeutics Drug 麻豆原创 Perspective (2018-2029)
2.2 Oligonucleotide Therapeutics Drug Growth Trends by Region
2.2.1 Global Oligonucleotide Therapeutics Drug 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oligonucleotide Therapeutics Drug Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Oligonucleotide Therapeutics Drug Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Oligonucleotide Therapeutics Drug 麻豆原创 Dynamics
2.3.1 Oligonucleotide Therapeutics Drug Industry Trends
2.3.2 Oligonucleotide Therapeutics Drug 麻豆原创 Drivers
2.3.3 Oligonucleotide Therapeutics Drug 麻豆原创 Challenges
2.3.4 Oligonucleotide Therapeutics Drug 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Therapeutics Drug Players by Revenue
3.1.1 Global Top Oligonucleotide Therapeutics Drug Players by Revenue (2018-2023)
3.1.2 Global Oligonucleotide Therapeutics Drug Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Oligonucleotide Therapeutics Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide Therapeutics Drug Revenue
3.4 Global Oligonucleotide Therapeutics Drug 麻豆原创 Concentration Ratio
3.4.1 Global Oligonucleotide Therapeutics Drug 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Drug Revenue in 2022
3.5 Oligonucleotide Therapeutics Drug Key Players Head office and Area Served
3.6 Key Players Oligonucleotide Therapeutics Drug Product Solution and Service
3.7 Date of Enter into Oligonucleotide Therapeutics Drug 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapeutics Drug Breakdown Data by Type
4.1 Global Oligonucleotide Therapeutics Drug Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Oligonucleotide Therapeutics Drug Forecasted 麻豆原创 Size by Type (2024-2029)
5 Oligonucleotide Therapeutics Drug Breakdown Data by Application
5.1 Global Oligonucleotide Therapeutics Drug Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Oligonucleotide Therapeutics Drug Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Oligonucleotide Therapeutics Drug 麻豆原创 Size (2018-2029)
6.2 North America Oligonucleotide Therapeutics Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2018-2023)
6.4 North America Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Therapeutics Drug 麻豆原创 Size (2018-2029)
7.2 Europe Oligonucleotide Therapeutics Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2018-2023)
7.4 Europe Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapeutics Drug 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Oligonucleotide Therapeutics Drug 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oligonucleotide Therapeutics Drug 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Oligonucleotide Therapeutics Drug 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Therapeutics Drug 麻豆原创 Size (2018-2029)
9.2 Latin America Oligonucleotide Therapeutics Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Therapeutics Drug 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Oligonucleotide Therapeutics Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Oligonucleotide Therapeutics Drug 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide Therapeutics Drug Introduction
11.1.4 Biogen Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Detail
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide Therapeutics Drug Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Detail
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide Therapeutics Drug Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Detail
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide Therapeutics Drug Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Drug Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Drug Business (2018-2023)
11.8.5 Akcea Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.